ArticleFrontiers in immunology2026
Association of the inflammatory marker suPAR with chronic pruritus of unknown origin - data from the SOMA.PRU study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic pruritus (CP) is a frequent and burdensome dermatological symptom that can occur both in skin conditions such as chronic atopic dermatitis (cAD) and as CP on non-lesional skin of unknown origin (CPUO). Mechanisms of pruritus chronicity remain poorly understood. In line with other persistent somatic symptoms, chronic systemic inflammation may play a role in CP. Soluble urokinase plasminogen activator receptor (suPAR) has been proposed as a marker of long-term systemic inflammation, but has not yet been studied in relation to CP. Objective: To study serum levels of suPAR in patients with CPUO in comparison to cAD and to study possible associations between suPAR levels and prospective clinical course. Methods: We analyzed data from 105 participants (35 CPUO, 40 cAD, 30 controls). Clinical and patient-reported outcomes were collected at baseline and at a six-months follow-up visit. Results: Patients with CPUO had the highest suPAR levels in our study (3.2 ± 2.5 ng/ml), showing a non-significant trend toward higher levels than controls (2.9 ± 1.1 ng/ml) and, despite similar pruritus intensity, significantly higher than participants with cAD (2.0 ± 0.9 ng/ml, Conclusion: This study indicates that systemic chronic inflammation is a relevant aspect of CPUO. In particular, we infer that suPAR may be a biomarker associated with the longitudinal course of CPUO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.